Company news

Axsome Therapeutics, Inc. news in 2022

Axsome Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 A...

December 6, 2022

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

November 27, 2022

Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 22, 2022

Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

November 8, 2022

Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 6, 2022

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

October 26, 2022

Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022

October 20, 2022

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

October 19, 2022

Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022

October 9, 2022

Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

October 2, 2022

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

September 28, 2022

Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

September 20, 2022

Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

September 13, 2022

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

September 7, 2022

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

September 6, 2022

Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

August 31, 2022

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

August 18, 2022

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 8, 2022

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 27, 2022

Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

June 27, 2022

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

June 21, 2022

Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting

June 5, 2022

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

June 1, 2022

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting

May 31, 2022

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

May 30, 2022

Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry

May 17, 2022

Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month

May 15, 2022

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

May 8, 2022

Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 1, 2022

Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine

May 1, 2022

Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022

April 24, 2022

Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience

March 27, 2022

Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum

March 10, 2022

Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

March 1, 2022

Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 28, 2022

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

February 14, 2022

Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Calls in 2022

Decks in 2022